Li Zhang, Ph.D.
Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Postdoctoral Fellow, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Postgraduate Training
| 2021-null | Postgraduate Fellow, The University of Texas MD Anderson Cancer Center, Houston, Texas |
Selected Publications
Abstracts
- Qian J, Soeung M, Yan X, Yu K, Zanca C, Zhang L, Chen Z, Perelli L, Chen J, Tidwell RS. Unravelling the mechanisms of resistance and hyperprogression of renal medullary carcinoma to immune checkpoint therapy, 2025. e-Pub 2025.
- Gurreri E, Zhang L, Khan H, Mustachio LM, Feng N, Heffernan T, Marszalek JR, Olca B, Basturk O, Klimstra D, Sioletic S. Investigating the role of allelic imbalance in pancreatic cancer aggressiveness, survival, and therapeutic resistance, 2025. e-Pub 2025.
- Soeung M, Yan X, Zhang L, Perelli L, Chen J, Tidwell BS, Khan H, Le CN, Lam TN, Bhattacharya N, Shah R, Ho I, Chen Z, Lundgren SR, Feng N, Zanca C, Karki M, Zacharias Millward NM, He R, Sheth RA, Tharakeswara BK, Rao P, Daw NC, Tripathi DN, Walker CL, Han G, Chu Y, Wang R, Dang M, Dai E, Peng F, Liu Y, Jadhav AS, Lang W, Arrechedera CA, Clemente LC, Parra-Cuentas ER, Lu H, Haymaker C, Wistuba II, Futreal A, Heffernan T, Viale A, Draetta GF, Tannir NM, Gao J, Wang L, Genovese G, Msaouel P. Hyperprogression due to myeloid mimicry in renal medullary carcinoma treated with nivolumab plus ipilimumab, 2024. e-Pub 2024.
Patient Reviews
CV information above last modified July 22, 2026